Telisotuzumab Vedotin Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Telisotuzumab Vedotin comprises 4 peer-reviewed publications across 2 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Neoplasms, and Carcinoma, Non-Small-Cell Lung. Most recent publication: Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial., J Clin Oncol, 2024.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
    Strickler JH, Weekes CD, Nemunaitis J, et al. · J Clin Oncol · 2019
    PubMed: PMID 30285518 · NCT02099058 · Neoplasms
  2. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
    Camidge DR, Morgensztern D, Heist RS, et al. · Clin Cancer Res · 2022
    PubMed: PMID 34426443 · NCT02099058 · Neoplasms
  3. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
    Camidge DR, Barlesi F, Goldman JW, et al. · J Clin Oncol · 2023
    PubMed: PMID 36288547 · NCT02099058 · Neoplasms
  4. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
    Camidge DR, Bar J, Horinouchi H, et al. · J Clin Oncol · 2024
    PubMed: PMID 38843488 · NCT03539536 · Carcinoma, Non-Small-Cell Lung

Publications by year

2019–2024: 4 publications.

2019
1
2022
1
2023
1
2024
1

Publications by indication

Neoplasms (3)

  • Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
    J Clin Oncol · 2023 · PMID 36288547 · NCT02099058
  • Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
    Clin Cancer Res · 2022 · PMID 34426443 · NCT02099058
  • First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
    J Clin Oncol · 2019 · PMID 30285518 · NCT02099058

Carcinoma, Non-Small-Cell Lung (1)

  • Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
    J Clin Oncol · 2024 · PMID 38843488 · NCT03539536

Publications by journal

All Telisotuzumab Vedotin publications (4)

2024 (1 paper)

  1. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
    Camidge DR, Bar J, Horinouchi H, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38843488 · NCT03539536 · Carcinoma, Non-Small-Cell Lung

2023 (1 paper)

  1. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
    Camidge DR, Barlesi F, Goldman JW, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36288547 · NCT02099058 · Neoplasms

2022 (1 paper)

  1. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
    Camidge DR, Morgensztern D, Heist RS, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 34426443 · NCT02099058 · Neoplasms

2019 (1 paper)

  1. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
    Strickler JH, Weekes CD, Nemunaitis J, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 30285518 · NCT02099058 · Neoplasms

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).